InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,667.20
(
0.64%
)
US TECH 100
19,853.60
(
0.00%
)
Dow Jones
40,954.48
(
1.85%
)
Brent Oil
83.36
(
0.05%
)
Bitcoin
65,335.91
(
0.38%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: BTH post# 12610

Friday, 09/16/2011 10:59:34 AM

Friday, September 16, 2011 10:59:34 AM

Post# of 80490
I don't know what the analysts are predicting, but I don't see ridaforolimus being very successful either. Yes, treatment options for sarcoma are limited, but the efficacy of ridaforolimus wasn't spectacular.

Technically, as a maintenance therapy only patients who have at least stable disease following first line chemotherapy would be eligible for treatment with ridaforolimus. So that narrows an already small patient population.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up